An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on Cognition

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-17

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This open label study aims to evaluate whether the consumption of probiotics can improve symptoms and overall quality of life in individuals experiencing cognitive decline symptoms, as well as to evaluate the effects of probiotics on blood-related biomarkers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID

NCT06348212

Long COVID Brain Fog Cognitive Change

NOT_YET_RECRUITING NA

Effect of Lactobacillus Paracasei PS23 on Improving Aging and Muscle Loss in the Elderly

NCT06062472

Elderly Muscle Loss Depression +1 more

COMPLETED NA

Probiotic Intervention on Gut Microbiota and Cognitive Functioning in Older Adults With a Mild Cognitive Impairment

NCT05859230

Mild Cognitive Impairment

UNKNOWN NA

Relationship Between Gut Microbiome, Probiotics, and Mild Cognitive Impairment

NCT04971096

Mild Cognitive Impairment (MCI)

TERMINATED NA

Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological

NCT06968299

Cognitive Functions Perceptual Disturbances Cognitive Function Abnormal Sleep +1 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lacticaseibacillus paracasei PS23 (PS23) is a specific strain of probiotic bacteria known for its potential health benefits, particularly in the context of aging and muscle health. Research suggests that it may improve cognitive function, reduce age-related muscle loss, and modulate the gut microbiota. Probiotic supplements like PS23 are being explored as potential therapeutic agents for age-related cognitive deficits. A prior study showed that PS23 supplementation delayed age-related cognitive decline in mice. Additionally, PS23 has shown antidepressant-like effects and has been found to enhance physical performance and promote muscle recovery following injury.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subjective Cognitive Decline (SCD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotics

Lacticaseibacillus paracasei PS23 one capsule daily for 12 weeks

Group Type EXPERIMENTAL

Lacticaseibacillus paracasei

Intervention Type DIETARY_SUPPLEMENT

one capsule daily for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lacticaseibacillus paracasei

one capsule daily for 12 weeks

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PS23

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 50 to 85 years who self-report experiencing signs of cognitive decline.
* No prior diagnosis of dementia or Alzheimer's disease (AD).
* Willing and able to comply with study assessments and requirements, and provide written informed consent.

Exclusion Criteria

* Use of antibiotics or probiotic powder, capsules, or tablets within the past month.
* Currently undergoing antibiotic treatment.
* Known allergy to dairy products.
* Presence of immunodeficiency or impaired immune function.
* Diagnosis of small intestinal bacterial overgrowth (SIBO).
* Determined unsuitable by the investigator, for example, initiation of any new medication or therapy during the study period, particularly those related to memory impairment or cognitive decline.

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes